The Icahn School of Medicine is named after Carl Icahn because of a $ 200 mil. gift Mr Icahn made to the school. It is not a medical development research lab for Carl Icahn. The PR states the research is one of many methods being studied. It is quite a stretch to imply this as a potential investment by Icahn, and it is quite a stretch to imply a member of Mr Icahn's family will develop breast cancer and be saved by CSBR's method. If you have any facts please share them.
PFE is licensing CSBR's method to do reserach. The job listing shows some commitment to the method. That was the point of the post - not to show competition.
Can you make a case for shorts to cover? Every quarter the GROSS profit is negative. That is before operational expenses and is a vary big reason not to cover.
Pfizer is hiring Director, In Vivo Pharmacology, Oncology.
Key efforts for this leader will be to:
1) Oversee development and use of mouse models of cancer including cell line derived xenografts, patient derived xenograft models, GEMMs, and orthotopic models to evaluate novel anticancer therapeutics
Remember last September when you posted, "Lets see how things wash out now that they have put the development costs behind them to get to 3,000+ per day. The reserves have grown 188%. I like getting money from the companies I invest in. If you don't like the company sell."
I guess you have changed your mind. The problem is they should have cut the dividend a long time ago and now it is too late. If they cut the dividend now then the comparison to Argent, which I believe is responsible for the sell-off, will become more intense and ENYTF will sell-off even more. Would be a good buying opportunity though...sit tight
The SEC filling specifically mentions exhibit 10.1 which is the agreement between CSBR and Pfizer. It says in the exhibit, "Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as ***
So if you want to know what is being held confidential, look for the ***.
For example, "Champions will license to Pfizer *** TumorGraft Models under the license".
It appears to me they are keeping the price to Pfizer confidential
This stock is worse than a bond. With copper prices low and a junior miner with rights, my guess is the mine will be delayed and won't come into play as expected. That means we are just a timber stock with no growth in production. Meantime company spent millions to buy additional acreage which means more dead money for years. Everybody on this board hated Gutstein but at least he tried to do something.
Yep - seriously. You may be surprised but their 2014 guidance is exactly the same as they provided in mid- January! When they provided that guidance the stock jumped. Doesn't mean this stock won't hit 50 mid February - but not on earnings.
Just two weeks ago the provided guidance on the 4th quarter so I don't think there will be any major surprises. I wouldn't bet against this stock but if you have the February 50 calls you are going to need some luck.